Sonoma Pharmaceuticals, Inc. Warrants
SNOAW
SNOAW was delisted on the 22nd of January, 2020.
5 hedge funds and large institutions have $1.12M invested in Sonoma Pharmaceuticals, Inc. Warrants in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$74K |
| 2 |
ICM
Ionic Capital Management
New York
|
+$73K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.9K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$7.4K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$6.78K |
Top Sellers
SNOAW Hedge Fund Activity: Q4 2016 in Review
5 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals, Inc. Warrants (SNOAW) for Q4 2016, worth a combined $1.12M.
Buyers outnumbered sellers: 5 funds opened new SNOAW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $74K.
- 5 institutional investors held Sonoma Pharmaceuticals, Inc. Warrants (SNOAW) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $1.12M of Sonoma Pharmaceuticals, Inc. Warrants stock for Q4 2016.
- 5 funds opened new Sonoma Pharmaceuticals, Inc. Warrants positions in Q4 2016 and 0 closed out, a net change of +5 holders.
- The largest Sonoma Pharmaceuticals, Inc. Warrants buyer in Q4 2016 was Anson Funds Management, an estimated $74K added.
Based on aggregated 13F filings for Q4 2016.